Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Hematology · Myeloproliferative Neoplasm, Unclassifiable

Managing Symptoms and Recognizing Emergencies

At a Glance

MPN-U symptoms such as fatigue, itching, night sweats, bone pain, early fullness, and spleen discomfort may be chronic, but sudden weakness, speech or vision changes, chest symptoms, limb swelling, or severe bleeding require emergency care.

Symptoms of Myeloproliferative Neoplasm, Unclassifiable (MPN-U) are highly variable because the disease itself is a “mixed” category [1]. Some people have no symptoms at all when they are diagnosed, while others experience significant physical challenges [2]. Because MPN-U can involve many different types of blood cell changes, it is important to understand what is typical for you and what requires immediate medical attention.

Common Day-to-Day Symptoms

Most symptoms of MPN-U are related to how the body reacts to the overproduction of blood cells and the resulting inflammation [3]. These “constitutional symptoms” are chronic but manageable.

  • Fatigue: This is the most common symptom, reported by up to 90% of patients across broader MPN populations [4]. It is often described as a deep, persistent exhaustion that does not always improve with rest.
  • Early Satiety and Spleen Issues: In about 44% of MPN-U cases in one study, the spleen becomes enlarged (splenomegaly) [5]. An enlarged spleen can press against your stomach, making you feel full after only a few bites of food (early satiety) or causing discomfort in the upper left side of your abdomen [6]. Spleen enlargement is partly due to the spleen trying to clear abnormal cells, but also due to extramedullary hematopoiesis—the body attempting to make blood outside the bone marrow [7].
  • Pruritus (Itching): Some patients experience intense itching, often triggered by a warm shower or bath [8].
  • Night Sweats and Bone Pain: Chronic inflammation can lead to drenching night sweats and a dull, aching sensation in the bones [9][10].

Tracking Your Symptoms: The MPN-10

Because symptoms can change slowly over time, doctors use a standardized symptom-burden tool called the MPN-10 (also known as the MPN-SAF TSS) [11]. This is a questionnaire where you rate 10 symptoms on a scale of 0 (absent) to 10 (worst imaginable) [12]:

  1. Fatigue
  2. Filling up quickly (Early satiety)
  3. Abdominal discomfort
  4. Inactivity
  5. Problems with concentration
  6. Night sweats
  7. Itching (Pruritus)
  8. Bone pain
  9. Fever
  10. Unintentional weight loss

By adding these scores together (for a total out of 100), you and your doctor can track the “burden” of your disease and see if a new treatment is helping [13][14]. Note that this is a symptom-burden tool, not a diagnostic test and not, by itself, a measure of progression.

Navigating Risks: When to Seek Help

While daily symptoms are frustrating, they are usually stable. However, people with MPNs are at a higher risk for thrombosis (blood clots) and hemorrhage (severe bleeding) [15][16].

🔴 Seek immediate emergency medical attention (Call your local emergency number or go to the ER) for the following:

Signs of a Blood Clot (Thrombosis)

  • Stroke/TIA: Sudden numbness or weakness (especially on one side of the body), sudden confusion, trouble speaking, or sudden vision changes [17][18].
  • Pulmonary Embolism (PE): Sudden shortness of breath, sharp chest pain that worsens when you breathe in, or coughing up blood [19][15].
  • Deep Vein Thrombosis (DVT): New swelling, pain, warmth, or redness in an arm or leg. Clots can present atypically or in both limbs, so do not wait for all symptoms to appear [15][19].

Signs of Severe Bleeding

  • Vomiting blood (may look like red liquid or dark coffee grounds) [20].
  • Black, tarry, or bloody stools.
  • Heavy bleeding from the nose or gums that does not stop after 10–15 minutes of firm pressure.

🟡 Contact your hematology team the SAME DAY for:

  • Abdominal Clot (Splanchnic Thrombosis): New, severe, or persistent abdominal pain; do not wait for a swollen belly, yellowing of the skin (jaundice), or vomiting as splanchnic thrombosis can present with pain alone [20][21].
  • Neurological Changes: A new severe or rapidly worsening headache, particularly if you take aspirin or an anticoagulant [18].
  • Bleeding Signs: Extensive or rapidly increasing bruising, or bleeding with low platelets [16].

🟢 Discuss at your next routine visit:
It is normal to feel anxious about every new sensation, but many symptoms can be discussed at your next scheduled appointment. The following are usually not an emergency, but contact your team if they are new, worsening, or unusual:

  • Mild Bruising: Small, flat bruises on your arms or legs that appear without a clear cause are common in MPN-U and usually don’t indicate a crisis, but discuss them at your visit to rule out medication effects or acquired von Willebrand syndrome [16].
  • Stable Fatigue: While debilitating, your usual level of fatigue is a sign of the chronic nature of the disease, not an acute medical emergency [4].
  • Occasional Headaches: Mild or “usual” tension headaches can be managed with your care team’s guidance.

A Note on Aspirin: Do not start, stop, or change doses of aspirin or an anticoagulant without your clinician’s advice. Aspirin is not automatically appropriate for every person with MPN-U and depends on prior thrombosis, age, cardiovascular risks, bleeding history, and actual phenotype.

Common questions in this guide

What symptoms can MPN-U cause?
MPN-U symptoms vary widely, and some people have no symptoms when they are diagnosed. Common problems include persistent fatigue, feeling full after a small amount of food, abdominal discomfort from an enlarged spleen, itching, night sweats, and bone pain.
How does the MPN-10 help monitor MPN-U?
The MPN-10, also called the MPN-SAF TSS, asks you to rate 10 symptoms from 0 (absent) to 10 (worst imaginable). The total score ranges from 0 to 100 and helps your doctor track symptom burden and whether treatment is helping; it is not a diagnostic test or, by itself, a measure of disease progression.
Which MPN-U symptoms could mean a blood clot?
Call your local emergency number or go to an emergency department for sudden one-sided weakness or numbness, confusion, trouble speaking, sudden vision changes, sudden shortness of breath, sharp chest pain that worsens with breathing, or coughing up blood. New swelling, pain, warmth, or redness in an arm or leg can also signal a clot and needs immediate attention.
What bleeding signs are an emergency with MPN-U?
Vomiting blood, including material that looks like coffee grounds, black or bloody stools, or heavy nose or gum bleeding that does not stop after 10 to 15 minutes of firm pressure can signal severe bleeding. Seek emergency medical help rather than waiting for a routine appointment.
When should I contact my hematology team the same day?
Contact your hematology team the same day for new severe or persistent abdominal pain, a new severe or rapidly worsening headache, or extensive or rapidly increasing bruising. This is especially important if you take aspirin or an anticoagulant or have a low platelet count, and abdominal clotting can cause pain without swelling, jaundice, or vomiting.
Are fatigue or mild bruises usually an MPN-U emergency?
Your usual stable fatigue and small, flat bruises are generally not an emergency, but mention them to your care team, especially if they are new, worsening, or unusual. Sudden changes, extensive or rapidly increasing bruising, or bleeding should prompt faster medical advice.
Should everyone with MPN-U take low-dose aspirin?
No. Do not start, stop, or change aspirin or an anticoagulant without your clinician’s advice. Whether low-dose aspirin is appropriate depends on your platelet count, history of clots or bleeding, age, cardiovascular risks, and specific MPN-U pattern.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current risk level for blood clots (thrombosis) or major bleeding?
  2. 2.Given my current platelet count, should I be taking low-dose aspirin or any other blood-thinning medication?
  3. 3.Can you help me set a 'baseline' symptom score using the MPN-10 tool so we can track changes over time?
  4. 4.If I notice my spleen feels larger or I'm getting full faster than usual, should that prompt an earlier appointment or just a mention at my next one?
  5. 5.In my specific case, what would you consider 'major bleeding' versus 'expected bruising'?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT.

    McLornan DP, Malpassuti V, Lippinkhof-Kozijn A, et al.

    British journal of haematology 2020; (190(3)):437-441 doi:10.1111/bjh.16537.

    PMID: 32108327
  2. 2

    Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice.

    Hargreaves R, Harrison CN, McLornan DP

    Current research in translational medicine 2022; (70(3)):103338 doi:10.1016/j.retram.2022.103338.

    PMID: 35217310
  3. 3

    Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.

    Talpaz M, Kiladjian JJ

    Leukemia 2021; (35(1)):1-17 doi:10.1038/s41375-020-0954-2.

    PMID: 32647323
  4. 4

    The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.

    Harrison CN, Koschmieder S, Foltz L, et al.

    Annals of hematology 2017; (96(10)):1653-1665 doi:10.1007/s00277-017-3082-y.

    PMID: 28780729
  5. 5

    The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.

    Gianelli U, Cattaneo D, Bossi A, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; (30(2)):169-179 doi:10.1038/modpathol.2016.182.

    PMID: 27739437
  6. 6

    Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the 'unclassifiable'.

    Oganesyan A, Madero-Marroquin R, Patel AA

    Current opinion in hematology 2026; (33(2)):45-50 doi:10.1097/MOH.0000000000000907.

    PMID: 41496466
  7. 7

    Management of Splanchnic Venous Thrombosis: An Update.

    Rühl H, Reda S

    Hamostaseologie 2026; (46(1)):71-77 doi:10.1055/a-2749-6835.

    PMID: 41702389
  8. 8

    Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.

    Bhuria V, Baldauf CK, Schraven B, Fischer T

    International journal of molecular sciences 2022; (23(6)) doi:10.3390/ijms23063206.

    PMID: 35328626
  9. 9

    Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese.

    Guaraná M, Soares A, Daumas A, et al.

    Hematology, transfusion and cell therapy 2022; (44(3)):321-327 doi:10.1016/j.htct.2020.10.966.

    PMID: 33483290
  10. 10

    Addressing symptom burden in myeloproliferative neoplasms.

    Tremblay D, Mesa R

    Best practice & research. Clinical haematology 2022; (35(2)):101372 doi:10.1016/j.beha.2022.101372.

    PMID: 36333066
  11. 11

    Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.

    Langlais BT, Mazza GL, Kosiorek HE, et al.

    Journal of hematology 2021; (10(5)):207-211 doi:10.14740/jh914.

    PMID: 34804309
  12. 12

    Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients.

    Le Gall-Ianotto C, Ficheux AS, Lippert E, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2023; (37(6)):1175-1183 doi:10.1111/jdv.18990.

    PMID: 36808754
  13. 13

    Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.

    Hudgens S, Verstovsek S, Floden L, et al.

    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2024; (27(5)):607-613 doi:10.1016/j.jval.2024.01.014.

    PMID: 38311180
  14. 14

    Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.

    Mesa R, Boccia RV, Grunwald MR, et al.

    Clinical lymphoma, myeloma & leukemia 2018; (18(9)):590-596 doi:10.1016/j.clml.2018.05.020.

    PMID: 30122202
  15. 15

    Thrombotic and Bleeding Complications in Myeloproliferative Neoplasms: An Integrated Clinical Perspective.

    Cohen O, Ellis MH

    Seminars in thrombosis and hemostasis 2026; doi:10.1055/a-2836-0670.

    PMID: 41856500
  16. 16

    A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.

    Rungjirajittranon T, Owattanapanich W, Ungprasert P, et al.

    BMC cancer 2019; (19(1)):184 doi:10.1186/s12885-019-5387-9.

    PMID: 30819138
  17. 17

    Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review.

    Song J, Huang C, Jia L, et al.

    BMC neurology 2024; (24(1)):386 doi:10.1186/s12883-024-03913-8.

    PMID: 39395952
  18. 18

    Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.

    Trifan G, Shafi N, Testai FD

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2018; (27(10)):2572-2578 doi:10.1016/j.jstrokecerebrovasdis.2018.05.052.

    PMID: 30056970
  19. 19

    Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.

    De Stefano V, Finazzi G, Barbui T

    Blood cancer journal 2018; (8(7)):65 doi:10.1038/s41408-018-0101-8.

    PMID: 29946112
  20. 20

    Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment.

    Custo S, Tabone E, Aquilina A, et al.

    Hamostaseologie 2024; (44(4)):242-254 doi:10.1055/a-2232-5480.

    PMID: 38354834
  21. 21

    Acute upper gastrointestinal bleeding due to portal hypertension in a patient with primary myelofibrosis: A case report.

    Chen Y, Kong BB, Yin H, et al.

    World journal of clinical cases 2024; (12(15)):2621-2626 doi:10.12998/wjcc.v12.i15.2621.

    PMID: 38817215

This page is for informational purposes only and does not constitute medical advice. Contact your hematology team or emergency services for guidance about your specific symptoms and situation.

Get notified when new evidence is published on Chronic myeloproliferative disease, unclassifiable.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.